INmune Bio to Present at Maxim Growth Summit Amid Key Regulatory Milestones
Event summary
- INmune Bio will attend the 2026 Maxim Growth Summit from October 12th to 14th in NYC.
- CEO David Moss will present on an Immunology & Inflammation Therapies Panel on October 14th.
- The company will meet with institutional investors and engage with Maxim research analysts.
- INmune Bio is advancing two late-stage product platforms: CORDStrom™ and XPro1595™.
The big picture
INmune Bio’s participation in the Maxim Growth Summit comes as it navigates critical regulatory milestones for its two lead platforms. The company’s focus on precision medicine and inflammation therapies aligns with broader industry trends toward targeted immunotherapies. Success in securing regulatory approvals and securing investor confidence will be key to its growth trajectory.
What we're watching
- Regulatory Progress
- The pace at which INmune Bio advances its MAA for CORDStrom™ in the UK and EU, alongside its BLA submission in the U.S., will determine its near-term valuation.
- Investor Sentiment
- How institutional investor meetings at the Maxim Growth Summit influence INmune Bio’s stock performance and access to additional funding.
- Clinical Execution
- Whether XPro1595™ can maintain its Fast Track designation momentum through its Phase 2b/3 registrational program in early Alzheimer’s disease.
Related topics
